HISENSE
24.4.2022 05:02:08 CEST | Business Wire | Press release
Hisense, a leading technology enterprise worldwide, became a global partner with Paris Saint-Germain in 2020. Since then, benefiting from this partnership, Hisense has gained much recognition and support from consumers and built stronger emotional connections with football fans worldwide. As a socially responsible enterprise, Hisense took a step further and elevated its partnership by donating multiple hi-tech devices to non-profit programs and became a patron of Paris Saint-Germain Endowment Fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220423005007/en/
Hisense Donated TVs to Fully Support and Nurture Youth Development
Hisense donated TVs to the Paris Saint-Germain Endowment Fund; these TVs were used in the Cantine Solidaire organized by the Paris Saint-Germain Endowment Fund in March 2022, where 200 teenagers were welcomed to the Parc des Princes. The event focused on equality, sport, culture, digital world, citizenship, and music with students treated to lunch and sports and leisure activities and a CV workshop.
Sabrina Delannoy, Deputy Director of the Paris Saint-Germain Endowment Fund, commented on this partnership: "We are delighted that the club's partners are interested in our projects and are committed to supporting us. It shows that members of the Paris Saint-Germain family share our values. Hisense is an example for others to follow, we hope to continue working altogether in the long-term."
Hisense to Fulfill Corporate Social Responsibility, Aims to Create a Better Sustainable World
Cédric Audebert, Vice President of Hisense France, said: "As a partner of Paris Saint-Germain, we are very interested in the social initiatives of the Paris Saint-Germain Endowment Fund. Sport is a means of sharing and expressing solidarity, two values that are essential to us. Our goal is to show unstinting support for Paris Saint-Germain Endowment Fund, and we urge all companies to come and join us."
Hisense devotes to charity and sustainable development worldwide, it has donated many high-tech home appliances exclusively for Paris Saint-Germain Endowment Fund programs. As part of the above donation, Hisense donated TVs for "PSG HOLIDAYS," provided better equipment for children to have better training experience; also, Hisense donated a large screen TV for ‘Red & Blue School program’, provided long-term support and better environment for after-school training.
Hisense has been upholding the people-oriented concept, actively supporting charities, focusing on social responsibility and striving to make new contributions to global sustainable development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220423005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom